MAPK15

Across TCGA pan-cancer cohorts, MAPK15 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAPK15 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher MAPK15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPK15 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KICH, SARC, and STAD are the cancer types where MAPK15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	OS	Median	All	0.175	0.745	.007	6	view →
STAD	OS	Median	II,III,IV	0.500	0.660	.004	6	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →
SKCM	DFS	Median	All	0.921	0.718	.034	3	view →
COAD	OS	Median	All	0.529	0.873	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAPK15–KICH (DFS)

Open the KICH breakdown →